Video Library

Search the Video Library

Filter by Date

Displaying Results 16 - 30 of 71

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

¿Cómo los subtipos histológicos del cáncer pulmonar de células no pequeñas alteran las recomendaciones en el estadio avanzado?

For our third video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss how NSCLC subtype (histology) can alter chemotherapy recommendations in advanced

We recently joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided provoking and educational discussions on

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided a provoking and educational discussion on FCR vs

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Joshua Brody, MD, Oncologist and Director, Assistant Professor of Medicine, Hematology & Medical Oncology at Mount Sinai Hospital spoke with GRACE about the question

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. John Kuruvilla, MD, Associate Professor, Princess Margaret Hospital, University Health Network in Toronto, Canada, spoke with GRACE about Chronic Lymphocytic Leukemia

¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of surveillance imaging in indolent lymphomas and chronic lymphocytic leukemia (CLL) (¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?). Stay tuned for more on our

¿Están activos moléculas inhibitorias como el de la muerte programada 1 (PD1) y el ligando de muerte programada 1 (PDL1) en el linfoma y en la leucemia linfocítica crónica (LLC)?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding inhibitory molecules like the programmed cell death protein 1 (PD1) and its ligand (PDL1), and if they are active in lymphoma and in chronic lymphocytic leukemia (¿Están activos moléculas inhibitorias como el de la muerte programada

Leucemia aguda mieloide (LMA) en la población de tercera edad.

GRACE sat down with Dr. Marco Ruiz to discuss information regarding acute myeloid leukemia (AML) in elderly patients (Leucemia aguda mieloide (LMA) en la población de tercera edad). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding when and who to refer for hematopoietic cell transplantation (HCT) (¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?). Stay tuned for more on our continuing video series with our Spanish speaking

¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias mieloproliferativas (NMP) en la leucemia mieloide aguda (LMA)?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of fms related tyrosine kinase 3 (flt3) and myeloproliferative neoplasms (MPN) mutations in acute myeloid leukemia (AML) (¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias

¿Existe una terapia de mantenimiento mejor sobre las demás?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there is a best maintenance therapy (¿Existe una terapia de mantenimiento mejor sobre las demás?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

¿Todos deberían de recibir un trasplante autólogo?

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding whether all patients should receive an autologous transplant (¿Todos deberían de recibir un trasplante autólogo?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in